CareDx, Inc. has reported a significant financial performance for the third quarter of 2026, showcasing a robust 39% increase in revenue compared to the same period last year. This growth is pivotal for the company, as it raises its annual revenue guidance, reflecting its expanding influence in the medical diagnostics field.

Based in Brisbane, California, CareDx is a prominent player in the medical laboratory services sector, specifically focusing on precision medicine diagnostics related to transplant, specialty oncology, and cell therapy. The company trades on the Nasdaq under the ticker symbol CDNA and is classified under the SIC code 8071, which pertains to services in medical laboratories.

According to the recent SEC filing (accession number 0001217234-26-000059), CareDx announced its financial results for the quarter ending September 30, 2026. The company reported total revenues of $139 million, a notable increase from the previous year. The press release highlighted that testing services revenue surged to $119 million, marking a 65% year-over-year growth. The volume of testing services also increased by 51%, reaching approximately 75,900 tests.

Additionally, CareDx reported a GAAP net income of $19 million, a significant rise from $2 million in the third quarter of 2025. The company also achieved an adjusted EBITDA of $30 million, compared to $15 million in the same quarter last year. Cash flow from operations was reported at $13 million, indicating strong operational efficiency.

The filing also noted that CareDx has closed its acquisition of Naveris, Inc. for $160 million in cash, along with potential contingent consideration of up to $100 million. This strategic acquisition is expected to bolster CareDx's capabilities in the diagnostics market.

John Hanna, President and CEO of CareDx, expressed optimism about the company's trajectory, stating, "We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy. We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth."

The updated corporate presentation, which is available on CareDx's website, reflects the company's current strategies and future plans as of September 30, 2026. However, the filing does not specify what immediate actions will follow this announcement.

As CareDx continues to expand its offerings and market presence, industry competitors in the medical laboratory sector may need to innovate and enhance their services to keep pace with the growing demand for precision medicine solutions. The financial results underscore the increasing importance of molecular diagnostics in healthcare, which could reshape competitive dynamics within the industry.